Jean‐Yves Pierga

机构：Université Paris Cité, Sorbonne Paris Cité, Institut Curie · ORCID：0000-0002-2863-9995

发表论文 736 篇 · 总被引 29546 次 · h-index 80

代表论文

Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial – BREASTIMMUNE-03 (2025 · The Breast · 被引 1)
Supplementary Figure S12 from Transcriptomic Insights into Lobular Breast Cancer Biology and Patient Outcomes: Analysis of the MINDACT Clinical Trial (2026)
Supplementary Figure S3 from Transcriptomic Insights into Lobular Breast Cancer Biology and Patient Outcomes: Analysis of the MINDACT Clinical Trial (2026)
Supplementary Figure S4 from Transcriptomic Insights into Lobular Breast Cancer Biology and Patient Outcomes: Analysis of the MINDACT Clinical Trial (2026)
Supplementary Figure S8 from Transcriptomic Insights into Lobular Breast Cancer Biology and Patient Outcomes: Analysis of the MINDACT Clinical Trial (2026)
Supplementary Tables S1-S18 from Transcriptomic Insights into Lobular Breast Cancer Biology and Patient Outcomes: Analysis of the MINDACT Clinical Trial (2026)